Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
AssigneesBaruch S. Blumberg Institute, Drexel University
InventorsJU-TAO GUO, XIAODONG XU, TIMOTHY M. BLOCK
Life of this patent
Estimating the term…
Abstract
The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection.
Claims8
1-14. (canceled)
A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one compound of formula (I):
- wherein
- R1 is H;
- R2 is selected from the group consisting of H, CH3, CF3, F and Cl;
- R3 is selected from the group consisting of H, CH3, F and Cl;
- R4 is selected from the group consisting of H, F, Cl and CH3;
- R5 is selected from the group consisting of H and Cl;
- R7 is selected from the group consisting of H, Cl, F and Br;
- R9 is selected from the group consisting of H, CH3, F and Cl;
- Rx is selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one compound of formula (II):
- wherein:
- Rx is selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one compound of formula (III):
- wherein:
- R10 is selected from the group consisting of H, CH3, Cl and Br;
- Ry is selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one compound of formula (IV):
Dependencies are inferred from the claim text.